NASDAQ:TELA - TELA Bio Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $18.00
  • Forecasted Upside: 47.18 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$12.23
▼ -0.45 (-3.55%)

This chart shows the closing price for TELA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New TELA Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TELA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TELA

Analyst Price Target is $18.00
▲ +47.18% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for TELA Bio in the last 3 months. The average price target is $18.00, with a high forecast of $18.00 and a low forecast of $18.00. The average price target represents a 47.18% upside from the last price of $12.23.

This chart shows the closing price for TELA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in TELA Bio. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/4/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/2/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/1/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/1/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/30/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/25/2021Canaccord GenuityReiterated RatingBuy$18.00High
11/11/2020Piper SandlerBoost Price TargetOverweight$17.00 ➝ $20.00Low
8/12/2020Piper SandlerBoost Price TargetOverweight$14.00 ➝ $17.00High
7/9/2020Jefferies Financial GroupBoost Price TargetBuy$17.00 ➝ $20.00Medium
6/18/2020JMP SecuritiesBoost Price TargetOutperform$20.00 ➝ $24.00High
6/10/2020Canaccord GenuityBoost Price TargetBuy$15.00 ➝ $20.00High
5/13/2020JMP SecuritiesLower Price TargetMarket Outperform$22.00 ➝ $20.00High
1/10/2020Piper SandlerReiterated RatingBuy$17.00Medium
12/3/2019Jefferies Financial GroupInitiated CoverageBuy$23.00Medium
12/3/2019JMP SecuritiesInitiated CoverageOutperform$22.00High
12/3/2019Canaccord GenuityInitiated CoverageBuy$19.00High
12/3/2019Piper Jaffray CompaniesInitiated CoverageOverweight$17.00High
(Data available from 11/27/2016 forward)

News Sentiment Rating

0.52 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/28/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 4 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
11/27/2021

Current Sentiment

  • 4 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
TELA Bio logo
TELA Bio, Inc., a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Read More

Today's Range

Now: $12.23
Low: $12.23
High: $12.40

50 Day Range

MA: $12.79
Low: $12.20
High: $13.66

52 Week Range

Now: $12.23
Low: $11.03
High: $18.00

Volume

1,252 shs

Average Volume

31,259 shs

Market Capitalization

$177.38 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.66

Frequently Asked Questions

What sell-side analysts currently cover shares of TELA Bio?

The following Wall Street sell-side analysts have issued reports on TELA Bio in the last twelve months: Canaccord Genuity, and Zacks Investment Research.
View the latest analyst ratings for TELA.

What is the current price target for TELA Bio?

1 Wall Street analysts have set twelve-month price targets for TELA Bio in the last year. Their average twelve-month price target is $18.00, suggesting a possible upside of 47.2%. Canaccord Genuity has the highest price target set, predicting TELA will reach $18.00 in the next twelve months. Canaccord Genuity has the lowest price target set, forecasting a price of $18.00 for TELA Bio in the next year.
View the latest price targets for TELA.

What is the current consensus analyst rating for TELA Bio?

TELA Bio currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TELA will outperform the market and that investors should add to their positions of TELA Bio.
View the latest ratings for TELA.

What other companies compete with TELA Bio?

How do I contact TELA Bio's investor relations team?

TELA Bio's physical mailing address is 1 GREAT VALLEY PARKWAY SUITE 24, MALVERN PA, 19355. The company's listed phone number is 484-320-2930 and its investor relations email address is [email protected] The official website for TELA Bio is www.telabio.com.